American Heart Journal
Volume 148, Issue 1 , Pages 43-51 , July 2004

Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design

  • Gregg C Fonarow, MD

      Affiliations

    • Department of Medicine, UCLA Medical Center, Los Angeles, Calif, USA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 LeConte Ave, Room 67-120 CHS, Los Angeles, CA 90095-1679, USA.
    • ,
  • William T Abraham, MD, FACP, FACC

      Affiliations

    • Division of Cardiology, Ohio State University, Columbus, Ohio, USA
    • ,
  • Nancy M Albert, RN, MSN

      Affiliations

    • George M. and Linda H. Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Wendy A Gattis, PharmD

      Affiliations

    • Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill, USA
    • ,
  • Barry Greenberg, MD

      Affiliations

    • USCD Medical Center–Hillcrest, University of California, San Diego, Calif, USA
    • ,
  • Chris M O'Connor, MD

      Affiliations

    • Division of Cardiology, Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Clyde W Yancy, MD

      Affiliations

    • Department of Medicine, University of Texas, Southwestern Medical Center, Dallas, Tex, USA
    • ,
  • James Young, MD

      Affiliations

    • Department of Cardiovascular Medicine, Heart Failure Section, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Received 6 August 2003 ,Accepted 9 March 2004.

References 

  1. Hunt SA, Baker DW, Chin MH, et al.  ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult (executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)). J Am Coll Cardiol. 2001;38:2101–2113
  2. CIBIS-II Investigators . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) (a randomised trial). Lancet. 1999;353:9–13
  3. Hjalmarson A, Goldstein S, Fagerberg B, et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure (the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group). JAMA. 2000;283:1295–1302
  4. CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure (results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)). N Engl J Med. 1987;316:1429–1435
  5. SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  6. Heart Failure Society of America . Heart Failure Society of America (HFSA) practice guidelines (HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches). J Card Fail. 1999;5:357–382
  7. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1–38A
  8. Fonarow GC. The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med. 2002;3(Suppl 3):S2–10
  9. Fonarow GC, Adams K, Strausser BP. ADHERE (Acute Decompensated Heart Failure National Registry) (rationale, design, and subject population). J Card Fail. 2002;8:S49
  10. Ahmed A, Allman RM, DeLong JF, et al.  Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J. 2002;95:703–710
  11. Bart BA, Ertl G, Held P, et al.  Contemporary management of patients with left ventricular systolic dysfunction (results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry). Eur Heart J. 1999;20:1182–1190
  12. Young JB. Unpublished data courtesy of Dr J.B. Young, Cleveland Clinic Health system CHF Beta-blocker Pilot Project, Hillcrest Hospital; 2002
  13. Innovations in CHF care, volume II: CHF disease management. Washington, DC: The Advisory Board; 2000
  14. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003;107:1570–5.
  15. Fonarow GC, Stevenson LW, Walden JA, et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol. 1997;30:725–732
  16. Fonarow GC, Gawlinski A, Moughrabi S, et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819–822
  17. Pearson RR, Horne BD, Maycock CA, et al.  An institutional heart failure medication program reduces future cardiovascular readmissions and mortality (an analysis of 19,083 heart failure patients). Circulation. 2001;104(Suppl II):II-838
  18. Whellan DJ, Gaulden L, Gattis WA, et al.  The benefit of implementing a heart failure disease management program. Arch Intern Med. 2001;161:2223–2228
  19. Gheorghiade M. IMPACT-HF trial: late-breaking results. Presented at American Heart Association Scientific Sessions Satellite Symposium, November 18, 2002, Chicago, Ill
  20. Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 2000;85:10–17A
  21. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease (the time is now). Circulation. 2001;103:2768–2770
  22. Ashton CM, Kuykendall DH, Johnson ML, et al.  The association between the quality of inpatient care and early readmission. Ann Intern Med. 1995;122:415–421
  23. Joint Commission on Accreditation of Healthcare Organizations. Overview of the Heart Failure (HF) Core Measure Set by Joint Commission on Accreditation of Healthcare Organizations. Available at: http://www.jcaho.org/pms/core+measures/hf_overview.htm. Accessed May 28, 2003
  24. Moser DK, Mann DL. Improving outcomes in heart failure (it's not unusual beyond usual care). Circulation. 2002;105:2810–2812
  25. Gottlieb SS, Fisher ML, Kjekshus J, et al.  Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation. 2002;105:1182–1188
  26. Krum H, Roecker EB, Mohacsi P, et al.  Effects of initiating carvedilol in patients with severe chronic heart failure (results from the COPERNICUS study). JAMA. 2003;289:712–718
  27. Krum H, Roecker EB, Mohacsi P, et al.  Efficacy and safety of initiating carvedilol in patients with severe chronic heart failure (results of COPERNICUS study. Presented at American Heart Association 75th Scientific Sessions, November 17–20, 2002, Chicago, Ill). Circulation. 2002;106:II-612
  28. Gattis W, O'Connor CM, Gheorghiade M. The initiation management predischarge process for assessment of carvedilol therapy for heart failure (IMPACT-HF) study (design and implications). Rev Cardiovasc Med. 2002;3(Suppl 3):S48–54
  29. Gattis WA OPTIMIZE-HF: a web-based registry and process-of-care intervention. Presented at: American Heart Association Scientific Sessions Satellite Symposium, November 15, 2002, Chicago, Ill
  30. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–63.
  31. Every NR, Frederick PD, Robinson M, et al. A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. J Am Coll Cardiol 1999;33:1886–94.
  32. Fonarow, GC. The acute decompensated heart failure national registry [ADHERE]: opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4:S21–30.
  33. Fonarow GC, Yancy CW, Chang SF. Variation in heart failure quality of care indicators among US hospitals: analysis of 230 hospitals in ADHERE. Circulation 2003;108:IV-447.

☆ Guest Editor for this manuscript was Rebecca J. Quigg, MD, Northwestern University Medical School, Chicago, Ill.Supported by GlaxoSmithKline, Philadelphia, Pa, with editorial support provided by Accel Healthcare Communications Inc, New York, NY.

PII: S0002-8703(04)00126-7

doi: 10.1016/j.ahj.2004.03.004

American Heart Journal
Volume 148, Issue 1 , Pages 43-51 , July 2004

Article Tools

* Image Usage & Resolution